Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Moon Kil Woong is currently a VP at a SME. Previously he was a tech stock consultant, VP of Research at ING, and sell side Director at Crédit Agricole Indosuez. Moon Kil Woong has a Masters in Public Administration from SJSU.
Currently Chief Analyst at CapGainr.com.
Dallas currently owns and operates as CEO an Austin-based enterprise consulting firm that specializes in private company lifecycle management, up to and including taking companies public, and in helping consult publicly traded companies ranging in market cap from $100 million to $500 million. He has a specialization in deal flow management and is often the referring and closing source of Joint Ventures and broader M&A.
Dallas often works directly with management teams and Boards of microcap and stressed equity companies in which he or members of his professional network are heavily invested. This includes helping with overall strategy, helping with capital structure management, helping facilitate liquidity, helping facilitate Joint Ventures and broader M&A, and helping restructure the business segments if necessary.
Recently Dallas has been interviewed by The Pittsburgh Business Times, The Banker, Columbus Business First, Houston Business Journal, The Deal, Energy Intelligence, and his tweets have been used by CNBC to highlight hot button issues regarding Carl Icahn, Bill Ackman, Nelson Peltz’s takeover attempts at DuPont, etc. Dallas has also been quoted and sourced to by StreetSweeper.org, Marcellus.com, MarcellusDrilling.com, Bakken.com, OilOnline.com, and other physical and online publications.
"One place of great inefficiency is in the stressed equity markets – or the markets in which a company appears as bankruptcy or a breakup is inevitable. As equities become stressed they often sell down to absurd levels of value that present, should there be value to be unlocked, opportunities for “venture level” returns. These often range in the 3X-10X range. With my unique ability to actually improve business outcomes by working directly with a company and management/Board I’m in a position, should I view the underlying business as salvageable, to directly improve the long-term viability of the company. I am NOT simply an investor in these names but an acting consultant. This allows me to “overlay my network” and to move the company away from a stressed or defaulting outcome and into an outcome probability that allows the equity price to move substantially higher. Identifying these opportunities has generated shareholders and investors thousands of percentage points in aggregate and is something I’m often recognized by paying subscribers for."
Bookmark QTR's new blog, where exclusive (and always FREE) content will be available: http://www.quoththeravenresearch.com
Visit QTR and check out trading ideas, commentary, and me arguing with idiots on Twitter: http://www.twitter.com/quoththeravensa
QTR's ARTICLES ARE BOUND BY SA'S CONTRIBUTOR POLICY IN ADDITION TO THIS ENTIRE LENGTHY, YET EXTREMELY PERTINENT ADD ON DISCLOSURE, WHICH SERVES AS BOTH A STANDALONE DISCLOSURE AND AN AMENDMENT TO ANY AND ALL DISCLOSURES ALREADY PRESIDING OVER SEEKING ALPHA:
Quoth the Raven's ("QTR") articles are the sole product of QTR and his personal, individual opinions. These articles are not associated with, in any way, the opinions, strategies, or works of QTR's employer, associates, or entities in any way otherwise related to QTR.
(i.e. This are solely my personal thoughts and opinions)
You agree that by reading Quoth the Raven's articles, you are acting at your OWN RISK. In NO EVENT should QTR be liable for any direct or indirect trading losses caused by any information contained in QTR's articles, StockTalks, or other internet-based dissemination methods. Information in QTR's articles are not an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction. QTR is not suggesting the transacting of any financial instruments and QTR suggests consulting your personal financial adviser with regards to any such transactions.
QTR makes no representations, and specifically disclaims all warranties, express, implied, or statutory, regarding the accuracy, timeliness, or completeness of any material contained in this site. Again, you should seek the advice of your personal financial adviser or a security professional regarding your stock transactions.
QTR does not, in any way, guarantee that he is providing all of the information that may be available on any topic written. QTR recommends, again, that you do your own due diligence and consult a registered financial adviser before buying or selling any security.
QTR most always holds a position in any of the securities profiled in his pieces and he constructs his SA disclosures in accordance with SA's Contributor Policy, to the best of his knowledge in order to maintain transparency and also to uphold and respect pertinent securities laws. QTR may or may not report when a position is initiated or covered. Each investor must make that decision based on his/her judgment of the market.
I am not a stockbroker or financial adviser. I am a casual investor making casual observations for the purpose of discussion and open communication and analysis of companies and stocks. All articles are my opinion only and are not suggestions to buy or sell any equity, bond, option or other financial instrument. QTR may have long or short positions in any tickers mentioned at any time and reserves the right to open, close, or modify positions at all time without notice. My conclusions are the result of my personal due diligence and have been wrong in the past. There are tons of unqualified people out there offering up financial advice and its your responsibility to sort through the BS. You don't hit the button to fill my orders and I don't hit yours, so no whining or praising over stocks covered by me.
Follow QTR on Twitter: https://twitter.com/QuoththeRavenSA
View QTR's Stock Picking Performance for every article at TipRanks:
Investing actively in the stock market since 1991 and becoming a "Nokia-millionaire" during the 1990's as they call us here in my home country Finland.
Motto: Buy low, sell high, enjoy life by giving happiness to your family & friends.
John Petersen is executive vice president and chief financial officer of ePower Engine Systems, Inc., a company that has developed, built and demonstrated an engine-dominant diesel-electric hybrid drivetrain for long-haul heavy trucks that promises fuel savings of 25 to 35 percent depending on terrain and payload.
John is a lawyer and accountant with over three decades of corporate finance, due diligence, M&A advisory and related legal services for manufacturers, innovators and investors in the energy storage and renewable energy sectors.
Over the last eight years John has earned a global following for his articles on the energy storage and alternative energy sectors. He has contributed to AltEnergyStocks, Seeking Alpha, The Street, NASDAQ.com and Batteries International Magazine. He currently works as a senior editor at InvestorIntel.
John is a 1979 graduate of the Notre Dame Law School and a 1976 graduate of the W.P. Carey School of Business at Arizona State University. He was admitted to the bar in 1980 and licensed to practice as a CPA in 1981. John’s diverse experience in corporate finance, natural resource development and energy storage give him a unique and sometimes unsettling perspective on the technical, economic and supply chain challenges of the battery industry.
My name is Mark B. Spiegel and I'm the Managing Member of Stanphyl Capital Management LLC. I can be reached at: mark (at) stanphylcap (dot) com. My Twitter feed is @markbspiegel
I have been a independent investor for the past several years. I currently do all of my own research and have been very successful at doing so. This is what I do for a living and am very happy and passionate about what I do when it comes to the market. Last year I was up over 100 percent on my portfolio and know that there isn't possibly going to e another year like 2013, but what we do as investors is take the good with the bad and make ends meet.
"If you need a friend in the market, then get a dog...it's trench warfare out there Sport and in here too..."
"The most valuable commodity I know of ... is information."
"Greed, for lack of a better word, is good. Greed is right, greed works. Greed clarifies, cuts through, and captures the essence of the evolutionary spirit..."
"What's worth doing is worth doing for money..."
- Gordon Gekko
"The Art of Speculation, like the Art of War, is all about Preparation.
Especially once the dogs are unleashed." - Get a Dog ... of War
Born June 27th 1935 in Vienna, Austria. The youngest singer in my family which sang with the von Trapp singers, of which the film Sound of Music was based. Maria (played by Julie Andrew) was actually my nanny before she married Capt von Trapp (played by Christopher Plumber) who was not in the navy of Austria since Austria, being a land locked country, had no navy.
The little boy "Kurt" in the film was actually me. My mom never sued Twentieth Century Fox for using our story without receiving payment. (the von Trapps never went over the Alps to Switzerland.. that was my family and me...the captain and his singing family went to Italy and from there came to America via London)
When arriving in USA we moved to Arlington VT. where my neighbor was Norman Rockwell. My mom disallowed me from sitting for him despite frequent invitations to do so. Second immortality lost. :-)
Graduated with honors(Wall Street Journal award) from Lafayette College in 1957. After attending med school became ER physician in Conn. hospital, on the night shift. Had a seat on the NYSE at the same time and commuted from the hospital to Wall Street daily. After a few years of this, left medicine to stay with the NYSE Stock exchange.
Was also partner with Leon Cooperman in a NYSE member firm in late sixties. Carl Ichan and other notables of Wall Street are on best friends list..
Traded money for many well known names on the street such as Peter Kellogg of Spear Leeds and Kellogg, etc.
Am only surviving founder of the CBOE opened In early 70's. Names of "stripp, strapp, iron condor, condor, straddle, strangle" were all names that were thought up and first used by me. Traded options long before the CBOE was founded.
Traded on the CBOE under acronym PPP (known as Peter Paul) till 1988.
Started a Classic Jaguar restoration company in 1988 till 2011.
Went back to trading my own account, off floor in 2008.
60 years trading experience. Have been an avid technician the entire 60 years. We use fundamentals, PE ratios, overall market conditions, Fibonacci retracements, Elliott Wave theory, my own mathematical formulas as well as my own technical chart work (5 minute, daily, weekly as well as yearly) charts in analyzing and preparing recommendations to buy sell or hold.
ALL OUR ARTICLES are and will contain material discussion on timing and will be geared for the short term trader as well as the long term investor. I am on my computers, monitoring live charts and financial news on a minute to minute basis every trading day, from pre-market trading opening to after-market trades and the final closing.
Unlike Seeking Alpha articles from other contributors, all our articles will be prepared for maximum gain and minimum loss by supplying sell and buy stop recommendations along with the original recommendation. These will be updated as necessary over future time intervals. All will be published and added to all our recommendations on an "as needed" basis as often as market forces cause the need for such alterations. The use of option strategies as adjuncts or substitutions for stock will also be used and discussed as well as updated as necessary, so the investor taking our advise will never be out there "on his own" after acting on our initial recommendation from Doc's Trading"..
Readers may contact me directly at: firstname.lastname@example.org or (cell)928 951 4779
Over 25 years in trading & investing from microcaps to big caps. Charts are always a good tell but fundamentals need to support. Jesse Livermore's book ""Reminiscences of a Stock Operator" should be a mandatory read for anyone who deals with the stock market. Remember that trend is your friend and to make sure to always to do some research on your own as it is your money after all. Right? I am on Twitter @ValueInvestorRN
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.